Mekonos has developed Iris™, an innovative system-on-a-chip platform that enables effective delivery of drug payloads(s) to individual cells through thousands of nano-needles. This high-tech methodology has a substantially higher delivery conversion rate than standard virus-based cell editing methods.
Now based in Silicon Valley, the novel micro-electromechanical system (MEMS) technology originated from a PhD research project at the University of Canterbury, and was further developed at Stanford University, the University of California Berkeley, and Novartis Research Labs. Innovations in cell and gene therapy are a major area of investment interest globally, as many large cell Biotechnology and Pharmaceutical companies are looking for the next generation drug delivery platforms. Combined with novel gene and cell therapy drugs, this technology improves upon the treatment of diseases with a genetic element, including cancers, at massive scale. Matū continues to support Mekonos in their executive and strategic capabilities.